- HCV treatment with direct-acting antivirals (DAAs) is safe and effective in liver transplant (LT), kidney transplant (KT), and dual liver kidney (DLK) transplant recipients.
Why this matters
- Real-world cohorts reflect a more diverse population than clinical trials.
- Data for 443 transplant recipients (LT, 78%; KT, 14%; DLK, 8%) with HCV participating in HCV-TARGET, a real-world, international, observational study.
- Most (87%) had HCV-1 (1a, 52%), 42% had cirrhosis, and 54% were treatment-experienced.
- Primary endpoint was sustained virologic response at 12 wk posttherapy (SVR12).
- Funding: University of Florida; University of North Carolina; AbbVie; Bristol Myers Squibb; Gilead; GlaxoSmithKline; Janssen; Kadmon; Merck.
- Ledipasvir/sofosbuvir (LDV/SOF; Harvoni) ± ribavirin (RBV) was most commonly use...